The average one-year price target for Cue Biopharma (NasdaqCM:CUE) has been revised to $5.10 / share. This is an increase of 25.00% from the prior estimate of $4.08 dated November 14, 2025.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $4.04 to a high of $6.30 / share. The average price target represents an increase of 828.79% from the latest reported closing price of $0.55 / share.
What is the Fund Sentiment?
There are 62 funds or institutions reporting positions in Cue Biopharma. This is an increase of 2 owner(s) or 3.33% in the last quarter. Average portfolio weight of all funds dedicated to CUE is 0.02%, an increase of 28.25%. Total shares owned by institutions increased in the last three months by 6.65% to 18,634K shares. 
The put/call ratio of CUE is 0.13, indicating a bullish outlook.
What are Other Shareholders Doing?
Bleichroeder holds 6,819K shares representing 8.66% ownership of the company. No change in the last quarter.
Catalytic Wealth RIA holds 3,432K shares representing 4.36% ownership of the company. In its prior filing, the firm reported owning 3,332K shares , representing an increase of 2.91%. The firm decreased its portfolio allocation in CUE by 67.40% over the last quarter.
VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 1,597K shares representing 2.03% ownership of the company. In its prior filing, the firm reported owning 717K shares , representing an increase of 55.09%. The firm increased its portfolio allocation in CUE by 49.90% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,560K shares representing 1.98% ownership of the company. No change in the last quarter.
Geode Capital Management holds 801K shares representing 1.02% ownership of the company. In its prior filing, the firm reported owning 692K shares , representing an increase of 13.56%. The firm decreased its portfolio allocation in CUE by 41.09% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
